Report Description Table of Contents Industry Report and Statistics (Facts & Figures) - Number of Therapies & ASP by Therapy Type & Route of Administration The global hormone replacement therapy market will witness a robust CAGR of 7.83%, valued at $24.97 billion in 2021, expected to appreciate and reach $49.25 billion by 2030, confirms Strategic Market Research. Hormone replacement therapy (HRT) is a treatment procedure for replacing and replenishing hormones in the human body that are at inadequate levels compared to those required for normal physiology. The most well-known application of HRT is in the treatment of menopause symptoms. In other words, Hormone replacement therapy is a medical procedure in which patients are given hormones to replace naturally occurring hormones or augment naturally occurring ones that are missing. In the case of females, this treatment is used to restore the hormone levels in women who are at the stage of menopause, allowing the body to operate normally. Hormone replacement therapy (HRT) uses hormones to replace natural hormones when the body's production is insufficient. For instance, hormone replacement therapy is usually given to thyroid patients and human growth hormone patients. Furthermore, HRT was often administered to menopausal women to alleviate indications such as night sweats, hot flushes, sleep disturbances, psychological and genito-urinary disorders (urinary frequency and vaginal dryness), and the prevention of osteoporosis. In addition, a survey of 2,000 American women aged 30 to 60 indicated that approximately 47% of the surveyed population experienced the symptoms of hormonal imbalance in 2019. Menopause is the most frequently reported consequence of age-related hormonal changes. It often begins around the age of 50 in women around the world. By the age of 50, the levels of oestrogen and progesterone produced by women significantly decrease. The pituitary gland compensates for the decline in oestrogen and progesterone production by increasing the output of follicle-stimulating hormone. Drivers The rise in prevalence of menopausal illness and increased awareness of post-menopausal difficulties among women are two significant factors driving the worldwide HRT market. The hormone replacement therapy market trend is being driven by a large increase in the incidence rate of hormonal abnormalities in newborns, adults, and the elderly. Moreover, disease like The Prader-Willi syndrome (PWS) affects one out of every 15,000 babies. Low-Dosevaginal estrogen therapy, topical estrogen therapy, hysterectomy with bilateral salpingo-oophorectomy, Systemic hormone therapy, and Bioidentical hormone replacement therapy are all the factors that drive the market globally. Restraints During the projected period, unfavorable effects of hormone replacement therapy are expected to restrain market expansion. The high expense of hormone replacement therapy and the risk of acquiring cancer from HRTs are expected to stifle global market growth. Risks involved in hormone replacement therapy include Heart disease, Stroke, Blood clots, and Breast cancer which are expected to restrain the market. Key Opportunity The need for bioidentical hormone replacement therapy and the use of telemedicine for hormone replacement therapy are projected to give a lucrative opportunity for the global hormone replacement therapy market to expand in the near future. Market Analysis Of Different Segments Covered in the Report By Route Of Administration Parenteral Oral Others Hormone Replacement Therapy Market By Therapy Type Human Growth Hormone Replacement Therapy Estrogen Hormone Replacement Therapy Thyroid Hormone Replacement Therapy Progestogen Hormone Replacement Therapy Testosterone Hormone Replacement Therapy By Indication Hypothyroidism Menopause Growth Hormone Deficiency Male Hypogonadism Others By Region North America United States Canada Mexico Europe Germany France Italy Switzerland UK Rest of Europe Asia-Pacific Japan China India Rest of Asia-Pacific LAMEA Brazil Israel South Africa Saudi Arabia Rest of LAMEA Based on Route Of Administration, the oral market segment accounted for the largest proportion of the hormone replacement treatment market in 2020 and is predicted to increase at the quickest rate over the forecast period. This is because oral administration of testosterone medications is highly favored, and oral medication is the most prevalent form of oestrogen replacement therapy. In terms of therapy type, estrogen hormone replacement therapy was the market leader in 2020. This is due to women's increased usage of estradiol products to help them maintain hormonal balance after menopause or hysterectomy. Dryness, burning, itching, and pain during intercourse are some of the vaginal symptoms of menopause that can be alleviated by oestrogen replacement hormone therapy. Estrogen can be taken as a Estrogenpill, gel, Estrogen patch, lotion, or spray. It has a good success rate in treating menopausal night sweats and hot flashes, around 45 percent of women aged 40 to 60 reported seeking medical advice on the benefits and drawbacks of utilizing hormone replacement therapy (HRT) after menopause. Menopause is predicted to expand at the quickest rate in terms of indication from 2021 to 2028, as there is a great advancement in the number of postmenopausal women and the expansion of the menopausal window from 40 to 55 years. In accordance to the American Congress of Obstetricians and Gynecologists, around 6,000 women reach menopause every day. According to World Health Organisation (WHO), around 15 million neonates are born prematurely, with approximately 85% of these children being underdeveloped. Hormone treatment is used in adults to treat disorders like short bowel syndrome and pituitary tumors. The North American market dominated the global hormone replacement therapy market in 2019 due to the rise in manufacturer’s release of various generic hormone replacement therapy medicines, an increase in the target population, and advances in drug delivery technologies, as well as the creation of new formulations. Also, because of the rising public awareness, the hormone replacement treatment market in Asia Pacific is expected to grow quickly in the future years. Emerging countries such as Japan, India, and China will play a significant role in market expansion. According to the NIH(National Institutes of Health), half of the postmenopausal women have used HRT at least once. In 2014, more than 2.5 million Americans received testosterone treatment, according to the American Academy of Family Physicians. In accordance to NIH, about half of all postmenopausal women in the United States had hormone replacement therapy (HRT) at some point in their life. In addition, roughly 1.3 million American women will enter the menopause phase each year by 2021, according to a study published in Statpearls. According to studies conducted by organizations such as Rose Research, the North American Menopause Society (NAMS), and Therapeutic MD, approximately one million women in the United States are currently using hormone replacement therapy, which is expected to rise to 2.5 million in the near future. According to a study published in the Journal of Menopausal Medicine in 2020, about 75 percent of women experience menopause symptoms between the ages of 45 and 55, resulting in decreased self-esteem. According to the World Population Ageing 2019 study, women will account for 54 percent of the global population aged 65 and over by 2050, with a life expectancy at birth of 74.7 years in 2019. According to the American Thyroid Association (ATA), more than 12% of the US population is expected to have a thyroid issue during their lifetime, and nearly 20 million Americans are impacted by thyroid illness each year. As a result of the significant prevalence of thyroid hormone imbalance among the people in the United States, the studied market in the region is predicted to grow. Hormone Replacement Therapy Market Competitive Landscape Analysis Abbott Laboratories Bayer Ag. Eli Lily And Company Hoffmann-La Roche Ltd. (Genentech, Inc.) Hisamitsu Pharmaceutical Co., Inc. (Noven Pharmaceuticals, Inc.) Merck Kgaa Mylan N.V. (Viatris Inc.) Novartis International Ag Novo Nordisk A/S Pfizer Inc. Hormone Replacement Therapy Market Report Coverage Report Attribute Details Forecast Period 2021 - 2030 The market size value in 2021 USD 24.97 billion The revenue forecast in 2030 USD 49.25 billion Growth rate CAGR of approximately 7.839% The base year for estimation 2021 Historical data 2015 – 2019 Unit USD Billion, CAGR (2021 - 2030) Segmentation By Route Of Administration, By Therapy Type, By Indication, By Region By Route Of Administration Oral, Parenteral, Others By Therapy Type Estrogen Hormone Replacement Therapy, Human Growth Hormone Replacement Therapy, Thyroid Hormone Replacement Therapy, Testosterone Hormone Replacement Therapy, Progestogen Hormone Replacement Therapy By Indication Menopause, Hypothyroidism, Male Hypogonadism, Growth Hormone Deficiency, Others By Region North America, Asia-Pacific, Europe, LAMEA Country Scope United States of America, Mexico, United Arab Emirates, United Kingdom, Germany, France, Canada, China, India, Japan, South Korea, Brazil, Argentina, Saudi Arabia, South Africa Company Usability Profiles Abbott Laboratories, Bayer Ag., Eli Lily And Company, Hoffmann-La Roche Ltd. (Genentech, Inc.), Hisamitsu Pharmaceutical Co., Inc. (Noven Pharmaceuticals, Inc.), Merck Kgaa, Mylan N.V. (Viatris Inc.), Novartis International Ag, Novo Nordisk A/S, Pfizer Inc. Recent Developments On August 16th, 2022, Akorn announced that it had successfully received FDA approval for launching its Generic-Cetrorelix Acetate in the form of Injection (0.25 mg quantity). Cetrorelix is one of the most effective chemicals used in hormone replacement therapy as it totally blocks the adverse impacts of a natural hormone, known as GnRH or gonadotropin-releasing hormone. During the treatment process of ovarian stimulation, premature ovulation can lead to the formation of eggs that are unsuitable for fertilization. The Cetrorelix Acetate present in the Injection blocks such kind of premature ovulation. In December 2020, The US FDA approved Myovant Sciences' Orgovyx (relugolix). Orgovyx (relugolix) is an orally administered treatment that prevents the pituitary gland from producing luteinizing hormone and follicle-stimulating hormone, decreasing the amount of testosterone produced by the testicles. This aids in the treatment of advanced prostate cancer in adults. In August 2020, Bayer AG announced the acquisition of KanDy Therapeutics Inc., which will help Bayer to expand its women's medicine pipeline by including menopausal treatment in its portfolio. In August 2020, the FDA (US Food and Drug Administration) authorized Sogroya (somapacitan), a human growth hormone (HGH) therapy for adults with growth hormone insufficiency that is administered once a week via injection under the skin. As a result, the region's analyzed market is projected to be driven by the high trend of product approvals. The Key Products that the Market Leaders Develop Name of the product Function Key Players THYROCAB It is used in curing hyperthyroidism Abbott Laboratories ANGELIQ It is used to reduce menopause symptoms Bayer Inc. Adakveo It is used to reduce the frequency of vasoocclusive crises (VOCs) in adults and pediatric patients. Novartis International Ag Frequently Asked Question About This Report What is the HRT market growth? The hormone replacement therapy market is Forecasted to grow at a CAGR of 7.3% from 2022 to 2030. How big is the HRT market size? The global hormone replacement therapy market was expected at USD 5.2 B in 2022 and is forecasted to reach 10.3 B in 2030. Which is the leading Indication type for the Hormone Replacement Therapy Market? The leading indication type for the hormone replacement therapy market is menopause. Menopause is an organic biological process that occurs in women, usually between the ages of 44 and 55 and is characterized by a decrease in estrogen and progesterone production. Who are the key players majorly operating in the Market? The key players majorly operating in the hormone replacement therapy market include Pfizer Inc., Novo Nordisk A/S, Eli Lilly and Company, Mylan N.V., Bayer AG, Abbott Laboratories, Merck & Co., Inc., Novartis AG, TherapeuticsMD, Inc., and Amgen Inc. Which is the leading Route of administration type for the Market? The leading route of administration type for the hormone replacement therapy market is the oral route. Oral hormone replacement treatment is quick and simple to administer, making it a popular choice among patients and healthcare providers alike. Other methods of administration, such as transdermal, parenteral, and vaginal, are available and may be recommended in some cases. Which market segment is leading the therapy type category of the Market? The market segment leading the therapy type category of the hormone replacement therapy market is estrogen replacement therapy. The most prevalent type of hormone replacement treatment is estrogen replacement therapy, which is used to address menopausal symptoms such as hot flashes, vaginal dryness, and mood disturbances. Sources https://www.un.org/en/development/desa/population/publications/pdf/ageing/WorldPopulationAgeing2019-Highlights.pdf https://www.who.int/news-room/fact-sheets/detail/preterm-birth https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3963523/ https://www.statpearls.com/ArticleLibrary/viewarticle/27522 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3830366/ Table of Contents 1. EXECUTIVE SUMMARY 1.1. Market Attractiveness 1.2. Understanding the Target Customers 1.3. CXO perspective 1.4. Global Hormone Replacement Therapy Market, Historical Market Size & Future Projections Analysis 1.5. Global Hormone Replacement Therapy Market, By Type 1.6. Global Hormone Replacement Therapy Market, By Mode of Delivery 1.7. Global Hormone Replacement Therapy Market, By Distribution Channel 1.8. Global Hormone Replacement Therapy Market, By Region 2. MARKET SHARE ANALYSIS 2.1. Top 20 Players with Revenue and Sales Volume 2.2. Market Share, 2023 3. SALES VOLUME (UNITS), ASP, BY REGION 3.1. North America (United States, Canada) 3.2. Europe (UK, Germany, France, Netherlands, Italy, Spain, Benelux, Rest of Europe) 3.3. Asia Pacific (China, Japan, South Korea, India, Australia, Rest of APAC) 3.4. Rest of the World 4. INVESTMENT OPPORTUNITIES IN THE MARKET 4.1. On Going Market Developments 4.2. Merger & Acquisition Trends 4.3. Key Investment Opportunities 4.4. Most Potential Segments from a Growth and Investment Perspective 5. MARKET INTRODUCTION 5.1. Definition 5.2. Scope of the Study 5.3. Market Structure 5.4. Macro Factor Indicator Analysis 5.5. Key findings 5.5.1. Top investment pockets 6. RESEARCH METHODOLOGY 6.1. Research Process 6.2. Primary Research 6.3. Secondary Research 6.4. Market Size Estimation 6.5. Forecast Model 7. MARKET DYNAMICS 7.1. Introduction 7.2. Drivers 7.3. Restraints 7.4. Opportunities 7.5. Challenges 7.6. Covid-19 Impact Analysis 8. GLOBAL HORMONE REPLACEMENT THERAPY MARKET ANALYSIS BY SEGMENT (REGION LEVEL ANALYSIS) 8.1. Overview 8.2. Global Hormone Replacement Therapy Historical Market Size ($MILLION), Sales Volume, ASP (2017 – 2021) 8.3. Global Hormone Replacement Therapy Market Size ($MILLION), Sales Volume, ASP and Forecasts (2023 – 2030) 8.4. Global Hormone Replacement Therapy Market Size ($MILLION), Sales Volume, ASP and Forecasts (2023 – 2030), By Type 8.4.1. Estrogen Replacement Therapy (ERT) 8.4.2. Testosterone Replacement Therapy (TRT) 8.4.3. Thyroid Hormone Replacement Therapy (THRT) 8.4.4. Growth Hormone Replacement Therapy (GHRT) 8.5. Global Hormone Replacement Therapy Market Size ($MILLION), Sales Volume, ASP and Forecasts (2023 – 2030), By Mode of Delivery 8.5.1. Oral 8.5.2. Parenteral 8.5.3. Transdermal 8.6. Global Hormone Replacement Therapy Market Size ($MILLION), Sales Volume, ASP and Forecasts (2023 – 2030), By Distribution Channel 8.6.1. Hospital pharmacies 8.6.2. Retail pharmacies 8.6.3. Online pharmacies 8.7. Global Hormone Replacement Therapy Market Size ($MILLION), Sales Volume, ASP and Forecasts (2023 – 2030), By Geography 8.7.1. North America 8.7.2. Asia Pacific 8.7.3. Europe 8.7.4. Rest of the World 9. NORTH AMERICA HORMONE REPLACEMENT THERAPY MARKET ANALYSIS 9.1. Overview 9.2. North America Hormone Replacement Therapy Historical Market Size ($MILLION), Sales Volume, ASP (2017 – 2021) 9.3. North America Hormone Replacement Therapy Market Size ($MILLION), Sales Volume, ASP and Forecasts (2023 – 2030) 9.4. North America Hormone Replacement Therapy Market Size ($MILLION), Sales Volume, ASP and Forecasts (2023 – 2030), By Type 9.4.1. Estrogen Replacement Therapy (ERT) 9.4.2. Testosterone Replacement Therapy (TRT) 9.4.3. Thyroid Hormone Replacement Therapy (THRT) 9.4.4. Growth Hormone Replacement Therapy (GHRT) 9.5. North America Hormone Replacement Therapy Market Size ($MILLION), Sales Volume, ASP and Forecasts (2023 – 2030), By Mode of Delivery 9.5.1. Oral 9.5.2. Parenteral 9.5.3. Transdermal 9.6. North America Hormone Replacement Therapy Market Size ($MILLION), Sales Volume, ASP and Forecasts (2023 – 2030), By Distribution Channel 9.6.1. Hospital pharmacies 9.6.2. Retail pharmacies 9.6.3. Online pharmacies 9.7. North America Hormone Replacement Therapy Market Size ($MILLION), Sales Volume, ASP and Forecasts (2023 – 2030), By Geography 9.7.1. USA 9.7.1.1. California 9.7.1.2. Texas 9.7.1.3. Florida 9.7.1.4. Pennsylvania 9.7.1.5. Illinois 9.7.1.6. North Carolina 9.7.1.7. Rest of the U.S. 9.7.2. Canada 9.7.3. Rest of North America 10. EUROPE HORMONE REPLACEMENT THERAPY MARKET ANALYSIS 10.1. Overview 10.2. Europe Hormone Replacement Therapy Historical Market Size ($MILLION), Sales Volume, ASP (2017 – 2021) 10.3. Europe Hormone Replacement Therapy Market Size ($MILLION), Sales Volume, ASP and Forecasts (2023 – 2030) 10.4. Europe Hormone Replacement Therapy Market Size ($MILLION), Sales Volume, ASP and Forecasts (2023 – 2030), By Type 10.4.1. Estrogen Replacement Therapy (ERT) 10.4.2. Testosterone Replacement Therapy (TRT) 10.4.3. Thyroid Hormone Replacement Therapy (THRT) 10.4.4. Growth Hormone Replacement Therapy (GHRT) 10.5. Europe Hormone Replacement Therapy Market Size ($MILLION), Sales Volume, ASP and Forecasts (2023 – 2030), By Mode of Delivery 10.5.1. Oral 10.5.2. Parenteral 10.5.3. Transdermal 10.6. Europe Hormone Replacement Therapy Market Size ($MILLION), Sales Volume, ASP and Forecasts (2023 – 2030), By Distribution Channel 10.6.1. Hospital pharmacies 10.6.2. Retail pharmacies 10.6.3. Online pharmacies 10.7. Europe Global Hormone Replacement Therapy Market Size ($MILLION), Sales Volume, ASP and Forecasts (2023 – 2030), By Region 10.7.1. Germany 10.7.2. UK 10.7.3. France 10.7.4. Spain 10.7.5. Italy 10.7.6. Benelux 10.7.7. Rest of Europe 11. ASIA PACIFIC HORMONE REPLACEMENT THERAPY MARKET ANALYSIS 11.1. Overview 11.2. Asia Pacific Hormone Replacement Therapy Historical Market Size ($MILLION), Sales Volume, ASP (2017 – 2021) 11.3. Asia Pacific Hormone Replacement Therapy Market Size ($MILLION), Sales Volume, ASP and Forecasts (2023 – 2030) 11.4. Asia Pacific Hormone Replacement Therapy Market Size ($MILLION), Sales Volume, ASP and Forecasts (2023 – 2030), By Type 11.4.1. Estrogen Replacement Therapy (ERT) 11.4.2. Testosterone Replacement Therapy (TRT) 11.4.3. Thyroid Hormone Replacement Therapy (THRT) 11.4.4. Growth Hormone Replacement Therapy (GHRT) 11.5. Asia Pacific Hormone Replacement Therapy Market Size ($MILLION), Sales Volume, ASP and Forecasts (2023 – 2030), By Mode of Delivery 11.5.1. Oral 11.5.2. Parenteral 11.5.3. Transdermal 11.6. Asia Pacific Hormone Replacement Therapy Market Size ($MILLION), Sales Volume, ASP and Forecasts (2023 – 2030), By Distribution Channel 11.6.1. Hospital pharmacies 11.6.2. Retail pharmacies 11.6.3. Online pharmacies 11.7. Asia Pacific Hormone Replacement Therapy Market Size ($MILLION), Sales Volume, ASP and Forecasts (2023 – 2030), By Region 11.7.1. China 11.7.2. Japan 11.7.3. Korea 11.7.4. India 11.7.5. Australia 11.7.6. Rest of APAC 12. REST OF THE WORLD HORMONE REPLACEMENT THERAPY MARKET ANALYSIS 12.1. Overview 12.2. Rest of the World Hormone Replacement Therapy Market Historical Market Size ($MILLION), Sales Volume, ASP (2017 – 2021) 12.3. Rest of the World Hormone Replacement Therapy Market Size ($MILLION), Sales Volume, ASP and Forecasts (2023 – 2030) 12.4. Rest of the World Hormone Replacement Therapy Market Size ($MILLION), Sales Volume, ASP and Forecasts (2023 – 2030), By Type 12.4.1. Estrogen Replacement Therapy (ERT) 12.4.2. Testosterone Replacement Therapy (TRT) 12.4.3. Thyroid Hormone Replacement Therapy (THRT) 12.4.4. Growth Hormone Replacement Therapy (GHRT) 12.5. Rest of the World Hormone Replacement Therapy Market Size ($MILLION), Sales Volume, ASP and Forecasts (2023 – 2030), By Mode of Delivery 12.5.1. Oral 12.5.2. Parenteral 12.5.3. Transdermal 12.6. Rest of the World Hormone Replacement Therapy Market Size ($MILLION), Sales Volume, ASP and Forecasts (2023 – 2030), By Distribution Channel 12.6.1. Hospital pharmacies 12.6.2. Retail pharmacies 12.6.3. Online pharmacies 12.7. Rest of the World Hormone Replacement Therapy Market Size ($MILLION), Sales Volume, ASP and Forecasts (2023 – 2030), By Region 12.7.1. Latin America 12.7.2. Middle East 12.7.3. Africa 13. COMPANY PROFILES 13.1. ABBOTT LABORATORIES 13.1.1. Company Overview 13.1.2. Company Snapshot 13.1.3. Operating business segments 13.1.4. Product offered and Revenue from Hormone Replacement Therapy Business 13.1.5. Key business performances, strategies and developments 13.2. ALLERGAN PLC 13.2.1. Company Overview 13.2.2. Company Snapshot 13.2.3. Operating business segments 13.2.4. Product offered and Revenue from Hormone Replacement Therapy Business 13.2.5. Key business performances, strategies and developments 13.3. AMGEN INC. 13.3.1. Company Overview 13.3.2. Company Snapshot 13.3.3. Operating business segments 13.3.4. Product offered and Revenue from Hormone Replacement Therapy Business 13.3.5. Key business performances, strategies and developments 13.4. BAYER AG 13.4.1. Company Overview 13.4.2. Company Snapshot 13.4.3. Operating business segments 13.4.4. Product offered and Revenue from Hormone Replacement Therapy Business 13.4.5. Key business performances, strategies and developments 13.5. ELI LILLY AND COMPANY 13.5.1. Company Overview 13.5.2. Company Snapshot 13.5.3. Operating business segments 13.5.4. Product offered and Revenue from Hormone Replacement Therapy Business 13.5.5. Key business performances, strategies and developments 13.6. F. HOFFMANN-LA ROCHE AG 13.6.1. Company Overview 13.6.2. Company Snapshot 13.6.3. Operating business segments 13.6.4. Product offered and Revenue from Hormone Replacement Therapy Business 13.6.5. Key business performances, strategies and developments 13.7. HISAMITSU PHARMACEUTICAL CO. INC. 13.7.1. Company Overview 13.7.2. Company Snapshot 13.7.3. Operating business segments 13.7.4. Product offered and Revenue from Hormone Replacement Therapy Business 13.7.5. Key business performances, strategies and developments 13.8. LUPIN PHARMACEUTICALS INC. 13.8.1. Company Overview 13.8.2. Company Snapshot 13.8.3. Operating business segments 13.8.4. Product offered and Revenue from Hormone Replacement Therapy Business 13.8.5. Key business performances, strategies and developments 13.9. MERCK & CO. INC. 13.9.1. Company Overview 13.9.2. Company Snapshot 13.9.3. Operating business segments 13.9.4. Product offered and Revenue from Hormone Replacement Therapy Business 13.9.5. Key business performances, strategies and developments 13.10. MYLAN N.V. 13.10.1. Company Overview 13.10.2. Company Snapshot 13.10.3. Operating business segments 13.10.4. Product offered and Revenue from Hormone Replacement Therapy Business 13.10.5. Key business performances, strategies and developments 13.11. NOVARTIS INTERNATIONAL AG 13.11.1. Company Overview 13.11.2. Company Snapshot 13.11.3. Operating business segments 13.11.4. Product offered and Revenue from Hormone Replacement Therapy Business 13.11.5. Key business performances, strategies and developments 13.12. NOVO NORDISK A/S 13.12.1. Company Overview 13.12.2. Company Snapshot 13.12.3. Operating business segments 13.12.4. Product offered and Revenue from Hormone Replacement Therapy Business 13.12.5. Key business performances, strategies and developments 13.13. PFIZER INC. 13.13.1. Company Overview 13.13.2. Company Snapshot 13.13.3. Operating business segments 13.13.4. Product offered and Revenue from Hormone Replacement Therapy Business 13.13.5. Key business performances, strategies and developments 13.14. TEVA PHARMACEUTICAL INDUSTRIES LTD. 13.14.1. Company Overview 13.14.2. Company Snapshot 13.14.3. Operating business segments 13.14.4. Product offered and Revenue from Hormone Replacement Therapy Business 13.14.5. Key business performances, strategies and developments 13.15. THERAPEUTICSMD INC. 13.15.1. Company Overview 13.15.2. Company Snapshot 13.15.3. Operating business segments 13.15.4. Product offered and Revenue from Hormone Replacement Therapy Business 13.15.5. Key business performances, strategies and developments 13.16. UPSHER-SMITH LABORATORIES LLC 13.16.1. Company Overview 13.16.2. Company Snapshot 13.16.3. Operating business segments 13.16.4. Product offered and Revenue from Hormone Replacement Therapy Business 13.16.5. Key business performances, strategies and developments 13.17. VERTICAL PHARMACEUTICALS LLC 13.17.1. Company Overview 13.17.2. Company Snapshot 13.17.3. Operating business segments 13.17.4. Product offered and Revenue from Hormone Replacement Therapy Business 13.17.5. Key business performances, strategies and developments 13.18. WEST-WARD PHARMACEUTICALS CORP. 13.18.1. Company Overview 13.18.2. Company Snapshot 13.18.3. Operating business segments 13.18.4. Product offered and Revenue from Hormone Replacement Therapy Business 13.18.5. Key business performances, strategies and developments 13.19. WYETH LLC (A SUBSIDIARY OF PFIZER INC.) 13.19.1. Company Overview 13.19.2. Company Snapshot 13.19.3. Operating business segments 13.19.4. Product offered and Revenue from Hormone Replacement Therapy Business 13.19.5. Key business performances, strategies and developments 13.20. YPSOMED AG 13.20.1. Company Overview 13.20.2. Company Snapshot 13.20.3. Operating business segments 13.20.4. Product offered and Revenue from Hormone Replacement Therapy Business 13.20.5. Key business performances, strategies and developments LIST OF TABLES (125 Tables) 1. TABLE: MARKET, BY Type of Hormone, 2023-2030 (USD MILLION) 2. TABLE: MARKET FOR Estrogen Replacement Therapy (ERT), BY REGION, 2023-2030 (USD MILLION) 3. TABLE: MARKET FOR Testosterone Replacement Therapy (TRT), BY REGION, 2023-2030 (USD MILLION) 4. TABLE: MARKET FOR Thyroid Hormone Replacement Therapy (THRT), BY REGION, 2023-2030 (USD MILLION) 5. TABLE: MARKET FOR Growth Hormone Replacement Therapy (GHRT), BY REGION, 2023-2030 (USD MILLION) 6. TABLE: MARKET, BY Mode of Delivery, 2023-2030 (USD MILLION) 7. TABLE: MARKET FOR Oral BY REGION, 2023-2030 (USD MILLION) 8. TABLE: MARKET FOR Parenteral, BY REGION, 2023-2030 (USD MILLION) 9. TABLE: MARKET FOR Transdermal, BY REGION, 2023-2030 (USD MILLION) 10. TABLE: MARKET, BY Distribution Channel, 2023-2030 (USD MILLION) 11. TABLE: MARKET FOR Hospital Pharmacies, BY REGION, 2023-2030 (USD MILLION) 12. TABLE: MARKET FOR Retail Pharmacies BY REGION, 2023-2030 (USD MILLION) 13. TABLE: MARKET FOR Online Pharmacies, BY REGION, 2023-2030 (USD MILLION) 14. TABLE: MARKET, BY REGION, 2023-2030 (USD MILLION) 15. TABLE: NORTH AMERICA MARKET, BY REGION, 2023-2030 (USD MILLION) 16. TABLE: NORTH AMERICA MARKET, BY TYPE, 2023-2030 (USD MILLION) 17. TABLE: NORTH AMERICA MARKET, BY MODE OF DELIVERY, 2023-2030 (USD MILLION) 18. TABLE: NORTH AMERICA MARKET, BY DISTRIBUTION CHANNEL, 2023-2030 (USD MILLION) 19. TABLE: USA MARKET BY TYPE, 2023-2030 (USD MILLION) 20. TABLE: USA MARKET, BY MODE OF DELIVERY, 2023-2030 (USD MILLION) 21. TABLE: USA MARKET, BY DISTRIBUTION CHANNEL, 2023-2030 (USD MILLION) 22. TABLE: CALIFORNIA MARKET, BY TYPE, 2023-2030 (USD MILLION) 23. TABLE: CALIFORNIA MARKET, BY MODE OF DELIVERY, 2023-2030 (USD MILLION) 24. TABLE: CALIFORNIA MARKET, BY DISTRIBUTION CHANNEL, 2023-2030 (USD MILLION) 25. TABLE: TEXAS MARKET BY TYPE, 2023-2030 (USD MILLION) 26. TABLE: TEXAS MARKET, BY MODE OF DELIVERY, 2023-2030 (USD MILLION) 27. TABLE: TEXAS MARKET, BY DISTRIBUTION CHANNEL, 2023-2030 (USD MILLION) 28. TABLE: FLORIDA MARKET BY TYPE, 2023-2030 (USD MILLION) 29. TABLE: FLORIDA MARKET, BY MODE OF DELIVERY, 2023-2030 (USD MILLION) 30. TABLE: FLORIDA MARKET, BY DISTRIBUTION CHANNEL, 2023-2030 (USD MILLION) 31. TABLE: CANADA MARKET, BY TYPE, 2023-2030 (USD MILLION) 32. TABLE: CANADA MARKET, BY MODE OF DELIVERY, 2023-2030 (USD MILLION) 33. TABLE: CANADA MARKET, BY DISTRIBUTION CHANNEL, 2023-2030 (USD MILLION) 34. TABLE: MEXICO MARKET, BY TYPE, 2023-2030 (USD MILLION) 35. TABLE: MEXICO MARKET, BY MODE OF DELIVERY, 2023-2030 (USD MILLION) 36. TABLE: MEXICO MARKET, BY DISTRIBUTION CHANNEL, 2023-2030 (USD MILLION) 37. TABLE: REST OF NORTH AMERICA MARKET, BY TYPE, 2023-2030 (USD MILLION) 38. TABLE: REST OF NORTH AMERICA MARKET, BY MODE OF DELIVERY, 2023-2030 (USD MILLION) 39. TABLE: REST OF NORTH AMERICA MARKET, BY DISTRIBUTION CHANNEL, 2023-2030 (USD MILLION) 40. TABLE: EUROPE MARKET, BY REGION, 2023-2030 (USD MILLION) 41. TABLE: EUROPE MARKET, BY TYPE, 2023-2030 (USD MILLION) 42. TABLE: EUROPE MARKET, BY MODE OF DELIVERY, 2023-2030 (USD MILLION) 43. TABLE: EUROPE MARKET, BY DISTRIBUTION CHANNEL, 2023-2030 (USD MILLION) 44. TABLE: GERMANY MARKET, BY TYPE, 2023-2030 (USD MILLION) 45. TABLE: GERMANY MARKET, BY MODE OF DELIVERY, 2023-2030 (USD MILLION) 46. TABLE: GERMANY MARKET, BY DISTRIBUTION CHANNEL, 2023-2030 (USD MILLION) 47. TABLE: FRANCE MARKET, BY TYPE, 2023-2030 (USD MILLION) 48. TABLE: FRANCE MARKET, BY MODE OF DELIVERY, 2023-2030 (USD MILLION) 49. TABLE: FRANCE MARKET, BY DISTRIBUTION CHANNEL, 2023-2030 (USD MILLION) 50. TABLE: UK MARKET, BY TYPE, 2023-2030 (USD MILLION) 51. TABLE: UK MARKET, BY MODE OF DELIVERY, 2023-2030 (USD MILLION) 52. TABLE: UK MARKET, BY DISTRIBUTION CHANNEL, 2023-2030 (USD MILLION) 53. TABLE: ITALY MARKET, BY TYPE, 2023-2030 (USD MILLION) 54. TABLE: ITALY MARKET, BY MODE OF DELIVERY, 2023-2030 (USD MILLION) 55. TABLE: ITALY MARKET, BY DISTRIBUTION CHANNEL, 2023-2030 (USD MILLION) 56. TABLE: SPAIN MARKET, BY TYPE, 2023-2030 (USD MILLION) 57. TABLE: SPAIN MARKET, BY MODE OF DELIVERY, 2023-2030 (USD MILLION) 58. TABLE: SPAIN MARKET, BY DISTRIBUTION CHANNEL, 2023-2030 (USD MILLION) 59. TABLE: REST OF EUROPE MARKET, BY TYPE, 2023-2030 (USD MILLION) 60. TABLE: REST OF EUROPE MARKET, BY MODE OF DELIVERY, 2023-2030 (USD MILLION) 61. TABLE: REST OF EUROPE MARKET, BY DISTRIBUTION CHANNEL, 2023-2030 (USD MILLION) 62. TABLE: ASIA PACIFIC MARKET, BY TYPE, 2023-2030 (USD MILLION) 63. TABLE: ASIA PACIFIC MARKET, BY MODE OF DELIVERY, 2023-2030 (USD MILLION) 64. TABLE: ASIA PACIFIC MARKET, BY DISTRIBUTION CHANNEL, 2023-2030 (USD MILLION) 65. TABLE: CHINA MARKET, BY TYPE, 2023-2030 (USD MILLION) 66. TABLE: CHINA MARKET, BY MODE OF DELIVERY, 2023-2030 (USD MILLION) 67. TABLE: CHINA MARKET, BY DISTRIBUTION CHANNEL, 2023-2030 (USD MILLION) 68. TABLE: INDIA MARKET, BY TYPE, 2023-2030 (USD MILLION) 69. TABLE: INDIA MARKET, BY MODE OF DELIVERY, 2023-2030 (USD MILLION) 70. TABLE: INDIA MARKET, BY DISTRIBUTION CHANNEL, 2023-2030 (USD MILLION) 71. TABLE: JAPAN MARKET, BY TYPE, 2023-2030 (USD MILLION) 72. TABLE: JAPAN MARKET, BY MODE OF DELIVERY, 2023-2030 (USD MILLION) 73. TABLE: JAPAN MARKET, BY DISTRIBUTION CHANNEL, 2023-2030 (USD MILLION) 74. TABLE: KOREA MARKET, BY TYPE, 2023-2030 (USD MILLION) 75. TABLE: KOREA MARKET, BY MODE OF DELIVERY, 2023-2030 (USD MILLION) 76. TABLE: KOREA MARKET, BY DISTRIBUTION CHANNEL, 2023-2030 (USD MILLION) 77. TABLE: AUSTRALIA MARKET, BY TYPE, 2023-2030 (USD MILLION) 78. TABLE: AUSTRALIA MARKET, BY MODE OF DELIVERY, 2023-2030 (USD MILLION) 79. TABLE: AUSTRALIA MARKET, BY DISTRIBUTION CHANNEL, 2023-2030 (USD MILLION) 80. TABLE: REST OF ASIA PACIFIC MARKET, BY TYPE, 2023-2030 (USD MILLION) 81. TABLE: REST OF ASIA PACIFIC MARKET, BY MODE OF DELIVERY, 2023-2030 (USD MILLION) 82. TABLE: REST OF ASIA PACIFIC MARKET, BY DISTRIBUTION CHANNEL, 2023-2030 (USD MILLION) 83. TABLE: REST OF THE WORLD MARKET, BY TYPE, 2023-2030 (USD MILLION) 84. TABLE: REST OF THE WORLD MARKET, BY TYPE, 2023-2030 (USD MILLION) 85. TABLE: REST OF THE WORLD MARKET, BY DISTRIBUTION CHANNEL, 2023-2030 (USD MILLION) 86. TABLE: Abbott Laboratories: COMPANY SNAPSHOT 87. TABLE: Abbott Laboratories: OPERATING SEGMENTS 88. TABLE: Allergan Plc: COMPANY SNAPSHOT 89. TABLE: Allergan Plc: OPERATING SEGMENTS 90. TABLE: Amgen Inc.: COMPANY SNAPSHOT 91. TABLE: Amgen Inc.: OPERATING SEGMENTS 92. TABLE: Bayer AG: COMPANY SNAPSHOT 93. TABLE: Bayer AG: OPERATING SEGMENTS 94. TABLE: Eli Lilly and Company: COMPANY SNAPSHOT 95. TABLE: Eli Lilly and Compan.: OPERATING SEGMENTS 96. TABLE: F. Hoffmann-La Roche AG: COMPANY SNAPSHOT 97. TABLE: F. Hoffmann-La Roche AG: OPERATING SEGMENTS 98. TABLE: Hisamitsu Pharmaceutical Co. Inc.: COMPANY SNAPSHOT 99. TABLE: Hisamitsu Pharmaceutical Co. Inc.: OPERATING SEGMENTS 100. TABLE: Lupin Pharmaceuticals Inc.: COMPANY SNAPSHOT 101. TABLE: Lupin Pharmaceuticals Inc.: OPERATING SEGMENTS 102. TABLE: Merck & Co. Inc.: COMPANY SNAPSHOT 103. TABLE: Merck & Co. Inc.: OPERATING SEGMENTS 104. TABLE: Mylan N.V.: COMPANY SNAPSHOT 105. TABLE: Mylan N.V.: OPERATING SEGMENTS 106. TABLE: Novartis International AG: COMPANY SNAPSHOT 107. TABLE: Novartis International AG: OPERATING SEGMENTS 108. TABLE: Novo Nordisk A/S: COMPANY SNAPSHOT 109. TABLE: Novo Nordisk A/S: OPERATING SEGMENTS 110. TABLE: Pfizer Inc.: COMPANY SNAPSHOT 111. TABLE: Pfizer Inc.: OPERATING SEGMENTS 112. TABLE: Teva Pharmaceutical Industries Ltd.: COMPANY SNAPSHOT 113. TABLE: Teva Pharmaceutical Industries Ltd.: OPERATING SEGMENTS 114. TABLE: TherapeuticsMD Inc.: COMPANY SNAPSHOT 115. TABLE: TherapeuticsMD Inc.: OPERATING SEGMENTS 116. TABLE: Upsher-Smith Laboratories LLC: COMPANY SNAPSHOT 117. TABLE: Upsher-Smith Laboratories LL: COPERATING SEGMENTS 118. TABLE: Vertical Pharmaceuticals LLC: COMPANY SNAPSHOT 119. TABLE: Vertical Pharmaceuticals LLC: OPERATING SEGMENTS 120. TABLE: West-Ward Pharmaceuticals Corp.: COMPANY SNAPSHOT 121. TABLE: West-Ward Pharmaceuticals Corp.: OPERATING SEGMENTS 122. TABLE: Wyeth LLC (a subsidiary of Pfizer Inc.): COMPANY SNAPSHOT 123. TABLE: Wyeth LLC (a subsidiary of Pfizer Inc.): OPERATING SEGMENTS 124. TABLE: Ypsomed AG: COMPANY SNAPSHOT 125. TABLE: Ypsomed AG: OPERATING SEGMENTS LIST OF FIGURES (43 Figures) 1. Figure: Market: Research Methodology Steps 2. Figure: Research Design 3. Figure: Breakdown of Primaries: Market 4. Figure: Research Methodology: Hypothesis Building 5. Figure: Market: Product and Service-Based Estimation 6. Figure: Top 20 Companies with Highest No. Of Patent in Last 9 Years 7. Figure: Growth Strategies Adopted by the Key Players 8. Figure: Top 20 Companies with Highest No. Of Patent in Last 9 Years 9. Figure: Growth Strategies Adopted by the Key Players 10. Figure: No. of Patents Granted Per Year, 2023–2030 11. Figure: Data Triangulation Methodology 12. Figure: Dominating Market Share, By TYPE, 2023 vs. 2030 (USD MILLION) 13. Figure: Dominating Market Share, By MODE OF DELIVERY, 2023 vs. 2030 (USD MILLION) 14. Figure: Dominating Market Share, By DISTRIBUTION CHANNEL, 2023 vs. 2030 (USD MILLION) 15. Figure: Geographical Snapshot of the Market 16. Figure: Estrogen to Witness Higher CAGR in the Market for TYPE Segment during the Forecast Period. 17. Figure: North America Accounted for the Largest Share of the Market, By Regional Basis, in 2023 18. Figure: Market: Drivers, Restraints, Opportunities, and Challenges 19. Figure: North America: Market Snapshot 20. Figure: Asia Pacific: Market Snapshot 21. Figure: Europe: Market Snapshot 22. Figure: Rest of the World: Market Snapshot 23. Figure: Vendor Dive: Evaluation Overview 24. Figure: Global Hormone Replacement Therapy: Competitive Benchmarking 25. Figure: Abbott Laboratories: Financial Overview (2023-2030) 26. Figure: Allergan Plc: Financial Overview (2023-2030) 27. Figure: Amgen Inc.: Financial Overview (2023-2030) 28. Figure: Bayer AG: Financial Overview (2023-2030) 29. Figure: Eli Lilly and Company: Financial Overview (2023-2030) 30. Figure: F. Hoffmann-La Roche AG: Financial Overview (2023-2030) 31. Figure: Hisamitsu Pharmaceutical Co. Inc.: Financial Overview (2023-2030) 32. Figure: Lupin Pharmaceuticals Inc.: Financial Overview (2023-2030) 33. Figure: Mylan N.V.: Financial Overview (2023-2030) 34. Figure: Novartis International AG: Financial Overview (2023-2030) 35. Figure: Novo Nordisk A/S: Financial Overview (2023-2030) 36. Figure: Pfizer Inc.: Financial Overview (2023-2030) 37. Figure: Teva Pharmaceutical Industries Ltd.: Financial Overview (2023-2030) 38. Figure: TherapeuticsMD Inc.: Financial Overview (2023-2030) 39. Figure: Upsher-Smith Laboratories LLC: Financial Overview (2023-2030) 40. Figure: Vertical Pharmaceuticals LLC: Financial Overview (2023-2030) 41. Figure: West-Ward Pharmaceuticals Corp.: Financial Overview (2023-2030) 42. Figure: Wyeth LLC (a subsidiary of Pfizer Inc.): Financial Overview (2023-2030) 43. Figure: Ypsomed AG: Financial Overview (2023-2030)